BRIEF-Amgen's Phase 3 A.R.R.O.W. study of once-weekly KYPROLIS regimen meets primary endpoint
October 23, 2017 at 16:05 PM EDT
* Phase 3 A.R.R.O.W. study of once-weekly KYPROLIS(carfilzomib) regimen meets primary endpoint of progression-free survival in relapsed and refractory multiple myeloma patients
